Nigerian Journal of Clinical Practice

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 22  |  Issue : 10  |  Page : 1324--1327

Clinical observation in edaravone treatment for acute cerebral infarction


Z Sun1, Q Xu2, G Gao3, M Zhao4, C Sun1 
1 Department of Neurology, Linzi District People's Hospital, Zibo, Shandong, China
2 Department of Neurology, Zibo Huajian Hospital, Zibo, Shandong, China
3 Linzi Zhutai Central Hospital, Zibo, Shandong, China
4 People's Hospital of Zhongmu, Zhengzhou, Henan, China

Correspondence Address:
Dr. Z Sun
Department of Neurology, Linzi District People's Hospital, Zibo, Shandong
China

Background: Acute cerebral infarction threats human health and life safety. The edaravone is a new antioxidant and hydroxyl radical scavenger, which is the novel scavenger for clinical use, mainly for nervous system diseases. Objective: The purpose of this study is to observe the clinical treatment effects of edaravone on the degree of improvement of neurological impairment and functional movement impairment in patients with acute cerebral infarction. Method: A total of 130 patients admitted to our hospital because of acute cerebral infarction from December 2015 to May 2017 were selected for group analysis. These patients were divided into a control group (n = 65) and a treatment group (n = 65) with a random odd–even method. The control group accepted conventional treatment, while the treatment group received edaravone treatment on top of the conventional treatment of the control group. After treatment, the differences in functional movement, living ability score, neurological score, treatment effect, and adverse reaction of these two groups were tested and compared. Results: The total treatment efficiency of conventional treatment in the control group was significantly lower than the combination treatment in the treatment group (P < 0.05). The inter-group differences in the National Institutes of Health Stroke Scale, activities of daily living, and Fugl–Meyer assessment scores after the treatment were significant between these two groups (P < 0.05). The posttreatment effect on the treatment group was superior to that on the control group (P < 0.05). The adverse reaction rate of the treatment group did not significantly vary from that of the control group (P > 0.05). Conclusion: Edaravone can significantly improve the degree of neurological impairment during acute cerebral infarction, functional movement, and living quality with a definite effect and high safety. Thus, this drug has a good prospect in clinical treatment.


How to cite this article:
Sun Z, Xu Q, Gao G, Zhao M, Sun C. Clinical observation in edaravone treatment for acute cerebral infarction.Niger J Clin Pract 2019;22:1324-1327


How to cite this URL:
Sun Z, Xu Q, Gao G, Zhao M, Sun C. Clinical observation in edaravone treatment for acute cerebral infarction. Niger J Clin Pract [serial online] 2019 [cited 2019 Nov 22 ];22:1324-1327
Available from: http://www.njcponline.com/article.asp?issn=1119-3077;year=2019;volume=22;issue=10;spage=1324;epage=1327;aulast=Sun;type=0